Both in Pharmaceuticals
Evolus vs Gyre Therapeutics
Over the past year EOLS returned +16.5% and GYRE returned −38.8%; their daily moves had a correlation of 0.21.
EOLS +16.5% GYRE −38.8%Growth of $1, one year, split-adjusted
| Metric | EOLS | GYRE |
|---|---|---|
| Price | $7.47 | $4.44 |
| Market cap | $493.4M | $470.8M |
| Today | +1.36% | 0.00% |
| 1 month | +1.2% | −37.3% |
| 6 months | +18.2% | −44.8% |
| Year to date | +12.3% | −37.1% |
| 1 year | +16.9% | −39.7% |
| Revenue growth (YoY) | +21.2% | −2.1% |
| Gross margin | 68.0% | 92.4% |
| Net margin | −9.6% | −40.1% |
| P/E (TTM) | — | — |
| Price / sales | 1.6× | 3.9× |
| Net cash | -$141.9M | $74.8M |
| Dividend yield | — | — |
| Volatility (60d) | 48.9% | 88.3% |
| Short % of float | 12.2% | 11.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).